Trial Profile
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Persistent Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Vorinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 14 May 2020 Status changed from active, no longer recruiting to completed.
- 07 Feb 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 28 May 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.